Structure Therapeutics Inc ADR Dossier
Qualitative Analysis
Business overview
Structure Therapeutics Inc. (NASDAQ: GPCR) is a clinical-stage global biopharmaceutical company focused on discovering and developing novel oral small molecule therapeutics to treat chronic metabolic and pulmonary diseases. The company leverages its next-generation structure-based drug discovery platform to target G-protein coupled receptors (GPCRs), which are historically difficult to target with small molecules. Its lead product candidate is aleniglipron (GSBR-1290), a once-daily oral small molecule GLP-1 receptor agonist designed to overcome the limitations of biologics and peptide therapies in the obesity and type 2 diabetes mellitus (T2DM) markets. Structure Therapeutics operates globally with key subsidiaries in the United States and China.
Research as of 19 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Advancing the lead oral small molecule GLP-1 receptor agonist, aleniglipron, into a Phase 3 registrational program for chronic weight management. The program is designed based on positive end-of-Phase 2 feedback from the FDA, utilizing a starting titration dose of 2.5 mg and evaluating multiple maintenance doses over a 52-week period across approximately 4,500 participants.
Expected impact: Aims to establish aleniglipron as a highly competitive, convenient, once-daily oral alternative to injectable GLP-1 therapies, capturing a share of the multi-billion dollar global obesity market.
Developing next-generation oral small molecule amylin receptor agonists (DACRAs) to address obesity. This includes advancing ACCG-2671 into Phase 2a development and initiating Phase 1 clinical trials for a second candidate, ACCG-3535, which features a unique chemical scaffold.
Expected impact: Establishes a robust foundation for future oral fixed-dose combination therapies (e.g., GLP-1 combined with amylin) to maximize weight loss efficacy and preserve lean mass.
Leveraging the company's structure-based drug discovery platform and computational chemistry expertise (in collaboration with Schrödinger) to discover and design novel oral small molecules targeting G-protein coupled receptors (GPCRs) for metabolic, cardiovascular, and pulmonary diseases.
Expected impact: Enables the continuous generation of high-quality, orally-available pipeline candidates that overcome the historical limitations of peptide-based therapeutics.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
High. Resolves potential intellectual property overlaps and validates Structure's robust patent portfolio in the oral GLP-1 space, while generating non-dilutive capital to fund the company's core clinical pipeline.
Terms: Genentech made a $100 million upfront payment to Structure's subsidiary, Gasherbrum Bio, in Q1 2026. Gasherbrum is also eligible to receive low-single-digit royalties on net sales of products containing CT-996 (an oral GLP-1 agonist acquired by Roche via Carmot Therapeutics).
High. Provides advanced computational chemistry and physics-based molecular modeling support to power Structure's GPCR-targeted drug discovery platform.
Terms: Ongoing collaborative research and software licensing terms.